Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: musculoskeletal disorders stem cell therapy - OrthoCyte

Drug Profile

Research programme: musculoskeletal disorders stem cell therapy - OrthoCyte

Alternative Names: OTX-CP03; OTX-CP07

Latest Information Update: 22 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OrthoCyte
  • Class Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Musculoskeletal disorders; Osteoarthritis

Most Recent Events

  • 17 Jan 2018 Stem cell therapy for musculoskeletal disorders is still in preclinical studies in USA
  • 17 Jan 2018 BioTime has patent protection for its Stem cell therapy for musculoskeletal disorders in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top